CSL - CSL Limited

[UMike]

LOL Buy on the rumor sell on the fact.
Bloomberg in their announcement boast that the half year results beat the experts expectations.

 

[divs4ever]

well i don't know what they were expecting , but the results weren't bad ( if memory serves me correctly up more than 10% in several areas )

maybe the analysts should pawn their rose-coloured glasses

 

[Belli]

Bloomberg in their announcement boast that the half year results beat the experts expectations.

That's code for "The experts got it wrong."

 

[Dona Ferentes]

"Dampened Near Term Growth Aspirations" for the recent acquisition

Vifor’s Injectafer intravenous iron deficiency treatment is facing competition from generic competitors as well as a budget-driven policy in the US that encourages doctors to promote cheaper treatments such as oral iron or a lower-dose injectable iron.

CSL was well-prepared for the generic competition but the regulatory headwinds had, for the time being, outweighed a potential “tailwind” from Injectafer being prescribed for heart failure, which would not be subject to the same budgetary constraint, CSL chief executive Paul McKenzie said.
.
and trading down 3 per cent, a bit above $280 a share

 

[rcw1]

Hmmmm
Might go back in soon ….

 

[divs4ever]

Double-digit returns collide with drug trial setback for CSL​

Double-digit returns collide with drug trial setback for CSL

CSL has delivered bumper returns once again in its half-year report but suffered a major setback this week.

www.livewiremarkets.com

 

[Dona Ferentes]

coming back up ... $287.

The core business of CSL Behring is the separation of human blood into components such as immunoglobulin from which it makes life-saving treatments for chronic immune system and bleeding disorders such as haemophilia. Seqirus is the second-largest part of CSL. Together, these account for about seven-eighths of CSL’s $US8.053 billion sales and $US3.787 billion group operating profit.

Vifor accounts for the remaining one-eighth of CSL’s sales and earnings, and kidney treatments less than half of that. Still, news this week that CSL had “dampened” its near term outlook for this business knocked several per cent off the shares.

CSL chief executive Paul McKenzie has no regrets about the buy: “We integrated them – no disruption to the business, $US2 billion in sales, good margin, lots of things to be happy with in a 12 month window. So we just need to bring the whole ecosystem together to really drive the ultimate value."

 

[UMike]

And then BANG down to $282.
Hopefully it is a slow steady ride back.

 

[Iggy_Pop]

CSL reported the failure of the AEGIS-II trial, which impacted the share price. Follwed up with a positive annaul report but share price still down for the month.

Iggy

 

[Sean K]

CSL reported the failure of the AEGIS-II trial, which impacted the share price. Follwed up with a positive annaul report but share price still down for the month.

Iggy

CSL letting you down a tad in the yearly comp. You'd have to guess that it will eventually break up from this chanel.

 

[DrBourse]

The following is a post I made a few hours ago in another Chat Room - thought some CSL tragics here may be interested....

Crawling back into The Cave now..

 

[divs4ever]

CSL prices US$1.25 billion in Corporate Bonds

CSL Limited (ASX:CSL; USOTC:CSLLY) today announces it has priced US$1.25 billion corporate bonds in the United States 144A / Reg S market.
The notes will be issued by CSL Finance Plc and guaranteed by the parent company, CSL Limited, and certain of its subsidiaries.
The principal amount, tenor and coupon for the notes are:
• US$500m 10-year at a fixed rate coupon of 5.106%
• US$750m 30-year at a fixed rate coupon of 5.417%

CSL intends to use the cash proceeds from the offering to refinance existing bank debt and the remainder for general corporate purposes.
Settlement of the notes is expected to occur on 3 April 2024, subject to customary closing conditions.

i do not hold this share

 

[Iggy_Pop]

CSL which is a quality company is struggling as a pick for the 2024 comp. I am still hopeful over the year to get some steady growth.

Iggy

 

[DrBourse]

The following is a post I made a few hours ago in another Chat Room - thought some CSL tragics here may be interested....

View attachment 171664
Crawling back into The Cave now..

Bingo - CSL Down to the 2nd Level Drop...

 

[Dona Ferentes]

CSL has been doing better than index over last 6 months

 

[JohnDe]

Had a short conversation with someone involved with investing in the health industry, reckons that Albanese's Future Made In Australia has spooked big investors into thinking that medium to long term money will move from medical research into solar panels and the like. Companies like CSL will experience a shortage of investment dollars, and thus reduced research & innovation.

 

[DrBourse]

$255.78 should be the next goal for CSL..

 

[JohnDe]

An article in today's paper rang true for me today. On Wednesday I decided that the CSL SP is low and could go lower for quite a while, but it is a quality company. On Thursday I put in a low order with the thought that I trade or invest depending on Monday's price and any new updates.

The risk of not taking risk

Just as markets have started to get bumpy on rising Middle East stresses and the shifting outlook for interest rates, billionaire investor Howard Marks has issued an important reminder. Going backward is part and parcel of moving forward. Or more bluntly: no pain no gain.
Marks, the co-founder and co-chairman of hedge fund Oaktree Capital with nearly $300bn under management - remember local fund giant Australian Super has a little over $315bn under management.

For decades, Marks has consistently spoken to his clients about the path to achieving investment outperformance. This has often involved changing positions, such as recently coming around to a view that bitcoin can be likened to gold or art - assets with no intrinsic value but hold significant value.

In his latest memo sent to investors, Marks says he was inspired by an article that appeared this month under the sports section in the Wall Street Journal: Chess Teaches the Power of Sacrifice.

As the title suggests, the piece written by chess grandmaster Maurice Ashley underscores the role that sacrifice plays in chess where most positions can’t be won or saved without giving another piece away. Intentionally losing a piece – the sacrifice – becomes part of the game plan, Marks says.

This can be in the form of “sham” sacrifices, where the trade-off is something tangible of value in return. Then there’s “real” sacrifices that involve a bigger leap of faith given gains are neither immediate nor tangible - however they may result in gaining ground or launching a bigger attack.

The analogy to investing becomes obvious pretty quickly, Marks says.

Buying a 10-year US bond might be “sham” sacrifice because while you give up your money for a decade, the same decision comes with the certainty of income. However, most other investments involve “real” sacrifice because often the risk of loss borne in pursuit of gains that are neither immediate nor tangible. Whatever the path of risk, not being willing to take risks is an extremely risky strategy. Marks puts this another way - the indispensability of risk. Or there’s the better known phrase: No pain, no gain.

Marks breaks this up into three choices for investors: The first is to avoid risk and have little or no return. Secondly, they can opt for modest risk and settle for modest return.

But the third path, earning high returns, requires that you bear meaningful risk - either in the possibility of loss in the chase for gains, or in professional investor terms underperformance in the pursuit of outperformance.

Most investors are capable of accomplishing the first and most of the second, Marks says.

But the challenge in investing lies in the pursuit of some version of the third point.

“Earning high returns – in absolute terms or relative to other investors in a market – requires that you bear meaningful risk”.

This is either “the possibility of loss in the pursuit of absolute gain or the possibility of underperformance in the pursuit of outperformance,” Marks says.

“There’s such a thing as the risk of taking too little risk. Most people understand this intellectually, but human nature makes it hard for many to accept the idea that the willingness to live with some losses is an essential ingredient in investment success,” he adds.

Applying this strategy, Marks says, investors must accept that success is likely to stem from making many investments, and they have to also accept there will be a portion of these investments that won’t succeed.

“You have to put it all out there. You have to take a shot. Not every effort will be rewarded with high returns, but hopefully enough will do so to produce success over the long term”.

The bottom line on the quest for superior investment returns is clear, Marks says. “You shouldn’t expect to make money without bearing risk, but you shouldn’t expect to make money just for taking risk. You have to sacrifice certainty, but it has to be done skilfully and intelligently, and with emotion under control,” Marks concludes.

 

[Iggy_Pop]

Macquarie came out this month and predicted CSL will rise to $500 in the next three years. With the correction in the ASX hopefully over for the moment, hopefully make some gains to help the yearly share tipping comp.

Iggy

 

[DrBourse]

C'mon CSL, Down to BELOW $271.20 again today - then, Maybe, DOWN to the next obvious levels within the ST..